Compare Alcon AG (ALC) vs Lennar Corporation (LEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Lennar Corporation — how do they compare? Alcon AG trades at $66.7 (market cap $32.69B), while Lennar Corporation trades at $83.33 (market cap $20.84B). The key difference: Alcon AG is the larger of the two by market cap, and Lennar Corporation pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| ALC | LEN | |
|---|---|---|
Market Cap | $32.69B | $20.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $142.40 |
52-Week Low | $62.02 | $82.30 |
Enterprise Value | $36.28B | $24.72B |
Dividend Yield | 0.54% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Lennar (LEN) trades at $86.74, down 1.67% on the day, with a bearish technical signal despite appearing undervalued on key metrics (P/E 13.83, P/S 0.67). Recent earnings have missed expectations, with Q2 2026 EPS expected at 1.32. The company faces margin pressure as it prioritizes sales volume over price, cutting average home prices to 2017 levels to boost affordability amid high mortgage rates.
While Lennar's valuation appears attractive and analyst consensus leans bullish (46% buy ratings), near-term risks include persistent housing affordability challenges, declining profit margins, and negative cash flow trends. Execution on margin recovery through cost discipline and faster cycle times will be crucial for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
